MediciNova Inc (NASDAQ: MNOV) is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, with a commercial focus on the United States market. The company has generated no product revenue and funds operations through equity financing, including a Standby Equity Purchase Agreement (SEPA) with Yorkville (YA II PN, LTD.) providing up to $30.0 million in common stock sales over 36 months from July 2025. MediciNova was incorporated in Delaware in September 2000 and carries an accumulated deficit of $438.7 million as of December 31, 2025. The company reported a net loss of $12.0 million for the year ended December 31, 2025, with total research, development, and patent expense of $7.155 million for the same period. As of December 31, 2025, MediciNova held $30.8 million in cash and cash equivalents. The company has no laboratory, research, or manufacturing facilities, relying entirely on third-party service providers for those functions.

Revenue model

MediciNova has no product revenue as of December 31, 2025. The company funds operations through equity issuances, including a SEPA with Yorkville allowing sales of up to $30.0 million in common stock at 97% of the lowest three-day VWAP over a 36-month period beginning July 2025. The long-term intended revenue model is licensing or strategic alliances with pharmaceutical partners following proof-of-concept Phase 2 clinical trials.

Products and services

MediciNova's two lead pipeline candidates are MN-166 (ibudilast), in development for neurological disorders including progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome; and MN-001 (tipelukast), in development for fibrotic and metabolic disorders including nonalcoholic fatty liver disease and hypertriglyceridemia. External development expense for MN-166 was $4.622 million and for MN-001 was $0.703 million for the year ended December 31, 2025.

Customers and end markets

MediciNova has no commercial customers as of December 31, 2025. Target end markets are patients with neurological disorders (progressive MS, ALS, glioblastoma) and metabolic or fibrotic diseases (NAFLD, hypertriglyceridemia). The company's commercial focus is the United States market.

Value-chain role

MediciNova operates as a clinical-stage drug developer with no manufacturing, laboratory, or research facilities of its own. All such services are contracted to third-party service providers. The company positions itself as a developer intending to out-license or partner assets with larger pharmaceutical companies following Phase 2 proof-of-concept results.

Geographic exposure

MediciNova maintains headquarters in San Diego, California (approximately 4,400 square feet, subleased through January 31, 2027) and an office in Tokyo, Japan. Its commercial development focus is the United States.

Source: SEC 10-K, filed 2026-03-10

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Annovis Bio Inc Rezolute Inc Candel Therapeutics Inc Lunai Bioworks Inc Greenwich Lifesciences Inc Biostax Corp. Shattuck Labs Inc